Commitment to Improving Oncology Care
The commitment to advancing oncology treatment and patient care is paramount at Sunesis, and it drives every aspect of our business.
- Our work—pursuing the best possible translational and clinical science to ensure that we deliver meaningful medicines to our patients
- Our workplace—creating a stimulating, teamwork-oriented environment for the employees involved in this important work
- Our community—supporting the larger oncology community and the philanthropic organizations that help patients and caregivers
Sunesis' principal focus is on realizing vosaroxin's transformative potential in the treatment of a disease that has seen little therapeutic advancement in the last 40 years. Beyond its Phase 3 VALOR trial, Sunesis supports a broad program of exploring the use of vosaroxin in additional patient settings and in novel combinations with leading treatment standards through ongoing investigator sponsored trials at leading U.S. centers. Sunesis has expanded its product pipeline to include company- and partner-directed development programs which provide the opportunity to expand and complement the vosaroxin franchise in oncology. These include TAK-580, a Pan-Raf inhibitor; SNS-062, a selective non-covalently binding oral inhibitor of Bruton's tyrosine kinase (BTK); and several potential first-in-class, pre-clinical inhibitors of the novel target phosphoinositide-dependent kinase-1 (PDK1).
We stress the importance of teamwork: developing and commercializing drugs is a complex, challenging process that requires open communication and a selfless pursuit of the truth. We seek to hire the best people and support them with ongoing education so they can help identify innovative solutions that will make a real difference to patients. Sunesis employees take inspiration from the real-life stories of patients who are fighting this disease and remain mindful of the true purpose of our work.
Sunesis is committed to participating in the larger community of people fighting cancer. We support philanthropic organizations whose mission is to assist patients and their loved ones. We also want to ensure that our patients are informed about their disease and how our medicines may help, and are aware of other resources that can help them.
We are also proud to sponsor the first-ever Acute Myeloid Leukemia Awareness Month in June in partnership with CancerCare. Click here to learn more about AML Awareness Month and Sunesis in the Community.